New pharmacological options in the chronic obstructive pulmonary disease
Keywords:
COPD, EXACERBATIONS, LAMA, MACROLIDESAbstract
Chronic obstructive pulmonary disease is a disseminated process with important clinical and economic implications. A bibliographic review of scientific articles published in PubMed, Scielo and MEDLINE between 2010 and 2015 was carried out concerning the inhalation treatment for the chronic obstructive pulmonary disease COPD), its main indications, adverse reactions and achievements of modern therapy. Recent clinical trials have led to the approval of new inhalation therapies for the disease. Many of these medicaments are combinations of long-acting beta antagonists and long-acting anticholinergics for the late stage of the COPD. The necessity of more investigations capable to establish comparisons between the available treatment options and the clinical relevance of new alternatives to improve the forced expired vital capacity is acknowledged.
Downloads
References
WHO. Chronic obstructive pulmonary disease (COPD) update. [en linea] 2016 [citado 1 de julio 2016]. Disponible en: http://www.who.int/respiratory/copd/en/.
Patel HJ. An Update on Pharmacologic Management of Chronic Obstructive Pulmonary Disease. CurrOpinPulmMed[revista en internet]. 2016 [citado 1 de julio 2016];22(2): 119-24. Disponible en: http://journals.lww.com/co-pulmonarymedicine/Abstract/2016/03000/An_update_on_pharmacologic_management_of_chronic.7.aspx.
Quint JK.Are Clinical Risk Scores for COPD Useful? BMJ OpenRespir Res[revista en internet]. 2015 [citado 1 de julio 2016]; 2(1): Disponible en:http://bmjopenrespres.bmj.com/content/2/1/e000072.extract.
Global Strategy for Diagnosis, Management, and Prevention of COPD–2016[en línea].2016 [citado 1 de Julio 2016].Disponible en:http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html.
MINSAP. Anuario estadístico de salud. Cuba. 2014. [en línea]Ministerio de salud pública. Dirección de registros médicos y de estadísticas de salud. La Habana. Cuba; 2015. p. 31-4 [citado 1 de julio 2016]. Disponible en: http://www.sld.cu/sitios/dne/.
Jones RC, Price D, Ryan D. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. LancetRespirMed[revista en internet]. 2014 [citado 1 de julio 2016];2(4): 267–76.Disponible en: http://www.sciencedirect.com/science/article/pii/S2213260014700086.
Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily b2-agonist, versus twice-daily b(2)-agonists or placebo for chronic obstructive pulmonary disease. Cochrane DatabaseSystRev[revista en internet]. 2015 [citado 1 de julio 2016]; 1:CD010139.Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010139.pub2/abstract.
Kornmann O, Dahl R, Centanni S. Once-daily indacaterol versus twicedailysalmeterol for COPD: a placebo-controlled comparison. EurRespir J [revista en internet]. 2011 [citado 1 de julio 2016]; 37(2):273–9.Disponible en: http://erj.ersjournals.com/content/37/2/273.short.
Vestbo J, Anderson JA, Calverley P. MA, Celli B, Ferguson GT. Jenkins, C. et al. Bias due to withdrawal in longtermrandomised trials in COPD: Evidence from the TORCH study. Theclinicalrespiratoryjournal[revista en internet]. 2011 [citado 1 de julio 2016]; 5(1): 44-9.Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1752-699X.2010.00198.x/full.
Maleki-Yazdi MR, Beck E, Hamilton AL. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting b2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. RespirMed[revista en internet]. 2015 [citado 1 de julio 2016]; 109(5):596–605.Disponible en: http://www.sciencedirect.com/science/article/pii/S095461111500075X.
Ferguson GT, Feldman GJ, Hofbauer P. Efficacy and safety of olodaterol once daily delivered via Respimat in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J ChronObstructPulmonDis[revista en internet]. 2014 [citado 1 de julio 2016]; 9:629–45.Disponible en: https://www.researchgate.net/profile/Paul_Sachs/publication/263433054_Efficacy_and_safety_of_olodaterol_once_daily_delivered_via_Respimat_in_patients_with_GOLD_2-4_COPD_Results_from_two_replicate_48-week_studies/links/54d791310cf25013d03a6891.pdf.
Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC)-Guía Española de la EPOC (GesEPOC). ArchBronconeumol [revista en internet]. 2012,Jun [citado 1 de julio 2016];48(Supl 1). Disponible en: http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90141716&pident_usuario=0&pcontactid=&pident_revista=6&ty=92&accion=L&origen=bronco&web=www.archbronconeumol.org&lan=es&fichero=6v48nSupl.1a90141716pdf001.pdf.
Reid DJ, Carlson AA. Clinical use of aclidinium in patients with COPD. Int J ChronObstructPulmonDis[revista en internet]. 2014 [citado 1 de julio 2016]; 9:369–379.Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010633/.
Tashkin DP, Leimer I, Metzdorf N, Decramer M. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. Respresearch[revista en internet]. 2015 [citado 1 de julio 2016]; 16(1): 65.Disponible en: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-015-0216-4.
Jones PW, Rennard SI, Agusti A. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res [revista en internet]. 2011 [citado 1 de julio 2016]; 12(1):55.Disponible en: http://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-55.
Jones PW, Singh D, Bateman ED. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. EurRespir J [revista en internet]. 2012 [citado 1 de julio 2016]; 40(4):830–6.Disponible en: http://erj.ersjournals.com/content/40/4/830.short.
Jones PW, Agusti A, Chanez P,Magnussen H, Fabbri L, Maroni J, et al. A phase III study evaluating aclidinium bromide, a novel long-acting antimuscarinic, in patients with COPD: ACCLAIM/COPD I. Am J RespirCrit Care Med [revista en internet]. 2009 [citado 1 de julio 2016]; 179: A6180.Disponible en: http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A6180.
Rennard S, Donohue J, Bateman E, Gross N, Garcia Gil E, Caracta C. Efficacy and safety of the novel, long-acting antimuscarinic, aclidinium bromide, in COPD patients in a phase III study: ACCLAIM/COPD II. Am J RespirCritCareMed[revista en internet]. 2009 [citado 1 de julio 2016]; 179: A6178.Disponible en: http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A6178.
Segreti A, Calzetta L, Rogliani P, Cazzola M. Umeclidinium for the treatment of chronic obstructive pulmonary disease. ExpRevRespirMed[revista en internet]. 2014 [citado 1 de julio 2016]; 8(6):665–71.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25312239.
Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. EurRespir J [revista en internet]. 2015 [citado 1 de julio 2016]; 43(1):72–81.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23949963.
Buhl R, Maltais F, Abrahams R. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). EurRespir J [revista en internet]. 2015 [citado 1 de julio 2016]; 45:969–79.Disponible en: http://erj.ersjournals.com/content/early/2015/01/08/09031936.00136014.short.
Aalbers R, Maleki-Yazdi MR, Hamilton A. Randomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the Respimat inhaler in patients with chronic obstructive pulmonary disease. AdvTher[revista en internet]. 2015 [citado 1 de julio 2016]; 32(9):809–22.Disponible en: http://link.springer.com/article/10.1007/s12325-015-0239-8.
Singh D, Ferguson GT, Bolitschek J. Tiotropium/ olodaterol shows clinically meaningful improvements in quality of life. RespirMed[revista en internet]. 2015 [citado 1 de julio 2016]; 109(10):1312–9.Disponible en: http://www.sciencedirect.com/science/article/pii/S0954611115300342.
Ferguson G, Clerisme-Beaty E, Groenke L, Voss F, Karpel J. Lung Function Response with Tiotropium+ Olodaterol Maintenance Treatment in Patients with COPD in the TONADO and OTEMTO Studies: a Subgroup Analysis by Age. CHEST Journal[revista en internet]. 2015 [citado 1 de julio 2016]; 148(4_MeetingAbstracts): 740A-740A.Disponible en: http://journal.publications.chestnet.org/article.aspx?articleid=2456997&resultClick=3.
D'Urzo AD, Rennard SI, Kerwin EM. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterolfumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res [revista en internet]. 2014 [citado 1 de julio 2016]; 15(1):123.Disponible en: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-014-0123-0.
Singh D, Jones PW, Bateman ED. Efficacy and safety of aclidinium bromide/formoterolfumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC PulmonMed[revista en internet]. 2014 [citado 1 de julio 2016]; 14:178.Disponible en: http://bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-14-178.
Bateman ED, Chapman KR, Singh D. Aclidinium bromide and formoterolfumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res [revista en internet]. 2015 [citado 1 de julio 2016]; 16(1):92.Disponible en: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-015-0250-2.
Celli B, Crater G, Kilbride S. Once-daily umeclidinium/vilanterol (UMEC/VIL) 125/25 mcg in COPD: a randomized, controlled study. CHEST Journal[revista en internet]. 2014 [citado 1 de julio 2016]; 145(5):981–91.Disponible en: http://journal.publications.chestnet.org/article.aspx?articleid=1809987&resultClick=3.
Decramer M, Anzueto A, Kerwin E. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidiniummonotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. LancetRespirMed[revista en internet]. 2014 [citado 1 de julio 2016]; 2(6):472–86.Disponible en: http://www.sciencedirect.com/science/article/pii/S2213260014700657.
Rodrigo GJ, Neffen H. A systematic review of the efficacy and safety of a fixeddose combination of umeclidinium and vilanterol for the treatment of COPD. CHEST Journal[revista en internet]. 2015 [citado 1 de julio 2016]; 148(2):397–407.Disponible en: http://journal.publications.chestnet.org/article.aspx?articleid=2203765.
Rodrigo GJ, Plaza V. Efficacy and safety of indacaterol and glycopyrronium in COPD: an update. CHEST Journal[revista en internet]. 2014 [citado 1 de julio 2016]; 146(2):e75.Disponible en: http://journal.publications.chestnet.org/article.aspx?articleid=1891817.
Mahler DA, Kerwin E, Ayers T. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J RespirCritCareMed[revista en internet]. 2015 [citado 1 de julio 2016]; 192(9):1068–79.Disponible en: http://www.atsjournals.org/doi/abs/10.1164/rccm.201505-1048OC.
Magnussen H, Watz H, Kirsten A. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale. RespirMed[revista en internet]. 2014 [citado 1 de julio 2016]; 108(4):593–9.Disponible en: http://www.sciencedirect.com/science/article/pii/S0954611114000225.
Yu T, Fain K, Boyd CM. Benefits and harms of roflumilast in moderate to severe COPD. Thorax[revista en internet]. 2014 [citado 1 de julio 2016]; 69:616–22.Disponible en: http://thorax.bmj.com/content/early/2013/12/17/thoraxjnl-2013-204155.short.
Martinez FJ, Calverley PM, Goehring UM. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomized controlled trial. Lancet[revista en internet]. 2015 [citado 1 de julio 2016]; 385(9971):857–66. Disponible en: http://www.sciencedirect.com/science/article/pii/S0140673614624107.
Albert RK, Connett J, Bailey WC. Azithromycin for prevention of exacerbations of COPD. New Engl J Med[revista en internet]. 2011 [citado 1 de julio 2016]; 365(8):689–98. Disponible en: http://www.nejm.org/doi/full/10.1056/nejmoa1104623.
Downloads
Published
How to Cite
Issue
Section
License
This journal provides free and immediate access to its content under the principle that making research freely available to the public supports a greater exchange of global knowledge. This means that the authors transfer the copyright to the journal, so that copies and distribution of the contents can be made by any means, as long as the authors' acknowledgment is maintained. These terms are a reflection that the journal assumes copyright under Creative Commons licenses, specifically under a Creative Commons Attribution 4.0 International license.
Registration and submission of articles to the journal is free. The processing, including review, editing and publication, is completely free of charge.